1. Effect of empagliflozin on efficacy parameters at week 18.
Effect of empagliflozin on efficacy parameters at week 18. A: Change from baseline in HbA1c (ANCOVA, FAS, LOCF imputation at week 18). B: Change from baseline in body weight (ANCOVA, FAS, LOCF). Data are mean ± SE at baseline and adjusted mean ± SE on treatment. Blue bars represent MDI insulin + placebo, purple bars represent MDI insulin + empagliflozin 10 mg, and green bars represent MDI insulin + empagliflozin 25 mg.
Julio Rosenstock et al. Dia Care 2014;37:
©2014 by American Diabetes Association